BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate
BioXcel Therapeutics Q1 2024 GAAP EPS $(0.87) Beats $(1.04) Estimate, Sales $582.000K Beat $464.000K Estimate
BioXcel Therapeutics 2024年第一季度GAAP每股收益美元（0.87美元）超过预期（1.04美元），销售额582.000万美元超过预期的464.000万美元
BioXcel Therapeutics (NASDAQ:BTAI) reported quarterly losses of $(0.87) per share which beat the analyst consensus estimate of $(1.04) by 16.35 percent. This is a 52.72 percent increase over losses of $(1.84) per share from the same period last year. The company reported quarterly sales of $582.000 thousand which beat the analyst consensus estimate of $464.000 thousand by 25.43 percent. This is a 182.52 percent increase over sales of $206.000 thousand the same period last year.
BioXcel Therapeutics（纳斯达克股票代码：BTAI）公布的季度亏损为每股0.87美元（0.87美元），比分析师普遍预期的1.04美元（1.04美元）高出16.35％。与去年同期每股亏损1.84美元（1.84）相比，增长了52.72％。该公司公布的季度销售额为58.2万美元，比分析师普遍预期的46.4万美元高出25.43％。这比去年同期的20.6万美元的销售额增长了182.52％。